nivolumab,ipilimumab,cabozantinib
bms,exelixis
['ipiniv', 'nivo', 'triplet,(-triplete)', 'rcc,(-irccs),(-srcc),(-urcc)', 'increase,(-increased)', 'cosmic-313']
cosmic-313: ipinivocabo vs ipinivo in 1l mrcc. meets primary endpoint (pfs). no os data presented. modest increase in rr, no differences in cr. significant tox with the triplet. #esmo22 
Medical Oncologist - Urologic Oncology. Hospital Universitario La Paz - IdiPAZ, Madrid